On this episode, we’re continuing our coverage of data presented at the 2023 ASCO Genitourinary Cancers Symposium, which took place recently in San Francisco. We’ll hear from three researchers about their findings in prostate cancer trials reported at the meeting.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we’re sharing news from our coverage of data presented at the 2023 ASCO Genitourinary Cancers Symposium, which took place recently in San Francisco. We’ll hear from two researchers about their findings in renal cell carcinoma (RCC).

To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we’re reviewing two recent U.S. Food and Drug Administration (FDA) approvals for patients with breast cancer: the February 3 approval of sacituzumab govitecan-hziy, and the January 27 approval of elacestrant.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

The 2023 ASCO Gastrointestinal Cancers Symposium took place from January 19 to 21 in San Francisco. On this episode, we’re hearing from the presenting authors of three studies reported at that meeting—the SUNLIGHT, SPOTLIGHT, and NAPOLI-3 trials—which examined novel regimens in colorectal cancer, gastric cancer, and pancreatic cancer, respectively.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, Chandrakanth Are, MBBS, MBA, FSSO, FRCS, FACS, Professor of Surgical Oncology and Global Health at University of Nebraska Medical Center, and an editorial advisor for The ASCO Post, holds a conversation with John H. Strickler, MD, a medical oncologist at Duke University Medical Center. The topic is the safety and efficacy of sotorasib, a KRAS G12C inhibitor, in previously treated patients with KRAS G12C–mutated pancreatic cancer, based on Strickler et al’s paper published on January 5th in The New England Journal of Medicine.

Coverage of stories discussed this week on ascopost.com:

Sotorasib in Previously Treated Patients With KRAS G12C–Mutated Advanced Pancreatic Cancer

To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we’re continuing our coverage of research presented at the 2022 ASH Annual Meeting and Exposition. Today, we’ll hear from several researchers about their findings in lymphoma.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we’re continuing our coverage of research presented at the 2022 ASH Annual Meeting and Exposition. Today, we’ll hear from several researchers about their findings in multiple myeloma.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we’re featuring authors discussing their impactful research presented at the 2022 ASH Annual Meeting and Exposition, focusing on findings in different subtypes of leukemia.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

This year’s San Antonio Breast Cancer Symposium took place last week. On this episode, we’re hearing from the authors of three high-impact studies that were presented at the meeting.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we’re reviewing U.S. Food and Drug Administration (FDA) approvals in oncology and hematology that occurred during the month of November.

To listen to more podcasts from ASCO, visit asco.org/podcasts.